Higher-risk profile Patients at higher risk from this combination include: those taking amlodipine 10 mg/day (the maximum approved dose), adults over 65 (CYP3A4 activity naturally declines with age [2]), anyone with a baseline systolic blood pressure at or below 130 mmHg on current therapy, patients taking other CYP3A4 inhibitors (azithromycin, fluconazole, grapefruit juice), and anyone with concurrent heart failure or severe aortic stenosis where cardiac output depends on adequate preload
Gao F, Koenitzer JR, Tobolewski JM, et al
2020 Dec 10;11:604179
Orandi, MD, PhD , associate professor of surgery and medicine at NYU Langone Health, about the studys implications and how clinicians may use GLP-1s to mitigate kidney disease and manage transplant outcomes
However, tirzepatides dual-pathway mechanism means it consistently outperforms single-pathway equivalent drugs in head-to-head trials
A recent large study reassessed 11 patients from 7 families 7,9,15 along with 6 new patients from 4 families